食管鳞癌患者NK细胞、T淋巴细胞水平检测及临床意义
|
摘要
目的检测食管鳞癌患者NK细胞、T淋巴细胞水平并分析其临床意义。方法选取2016年4月至2018年1月郑州大学第一附属医院收治的84例食管鳞癌患者作为食管癌组,选择同期于郑州大学第一附属医院体检的84例健康者作为对照组。检测两组外周血NK细胞(CD56~+)、T淋巴细胞(CD8~+、CD4~+、CD3~+)水平,分析其临床意义。结果食管癌组CD56~+、CD8~+水平较对照组高,CD4~+、CD3~+水平较对照组低,差异有统计学意义(P<0.001)。食管癌组Ⅲ期患者CD56~+、CD8~+水平高于Ⅰ、Ⅱ期,Ⅱ期患者CD56~+、CD8~+水平高于Ⅰ期,差异有统计学意义(P<0.05)。食管癌组Ⅲ期患者CD4~+、CD3~+水平低于Ⅰ、Ⅱ期,Ⅱ期患者CD4~+、CD3~+水平低于Ⅰ期,差异有统计学意义(P<0.05)。食管癌组有无淋巴结转移患者CD8~+、CD4~+、CD3~+、CD56~+水平比较,差异无统计学意义(P>0.05)。结论食管鳞癌患者细胞免疫功能下降,且细胞免疫功能随临床分期增加而下降。
Objective To detect NK cell and T lymphocyte levels in patients with esophageal squamous cell carcinoma and analyze the clinical significance.Methods A total of 84 patients with esophageal squamous cell carcinoma admitted to the First Affiliated Hospital of Zhengzhou University from April of 2016 to January of 2018 were selected as esophageal cancer group. A total of 84 healthy persons who underwent physical examination in the First Affiliated Hospital of Zhengzhou University were selected as control group at the same time. NK cell(CD56~+) and T lymphocyte(CD8~+, CD4~+, CD3~+) levels in peripheral blood of patients were detected and analyzed.Results The levels of CD56~+ and CD8~+ in esophageal cancer group were higher than those in control group, and the levels of CD4~+,CD3~+ were lower than those in control group, and the differences were statistically significant(P<0.001). The levels of CD56~+ and CD8~+ in stage Ⅲ patients in esophageal cancer group were higher than those in stage Ⅰ and Ⅱ, and the levels of CD56~+ and CD8~+ in stage Ⅱ patients were higher than those in stage Ⅰ, and the differences were statistically significant(P<0.05). The levels of CD4~+ and CD3~+ in stage Ⅲ patients in esophageal cancer group were lower than those in stage Ⅰ and Ⅱ, and the level of CD3~+ in stage Ⅱ patients was lower than that in stage Ⅰ, and the differences were statistically significant(P<0.05). The CD8~+, CD4~+, CD3~+ and CD56~+ levels were compared between patients with or without lymph node metastasis in esophageal cancer group, and the differences were statistically significant(P>0.05).Conclusion The cellular immune function of patients with esophageal cancer declines, and the cellular immune function decreases with the increase of clinical stages.
Objective To detect NK cell and T lymphocyte levels in patients with esophageal squamous cell carcinoma and analyze the clinical significance.Methods A total of 84 patients with esophageal squamous cell carcinoma admitted to the First Affiliated Hospital of Zhengzhou University from April of 2016 to January of 2018 were selected as esophageal cancer group. A total of 84 healthy persons who underwent physical examination in the First Affiliated Hospital of Zhengzhou University were selected as control group at the same time. NK cell(CD56~+) and T lymphocyte(CD8~+, CD4~+, CD3~+) levels in peripheral blood of patients were detected and analyzed.Results The levels of CD56~+ and CD8~+ in esophageal cancer group were higher than those in control group, and the levels of CD4~+,CD3~+ were lower than those in control group, and the differences were statistically significant(P<0.001). The levels of CD56~+ and CD8~+ in stage Ⅲ patients in esophageal cancer group were higher than those in stage Ⅰ and Ⅱ, and the levels of CD56~+ and CD8~+ in stage Ⅱ patients were higher than those in stage Ⅰ, and the differences were statistically significant(P<0.05). The levels of CD4~+ and CD3~+ in stage Ⅲ patients in esophageal cancer group were lower than those in stage Ⅰ and Ⅱ, and the level of CD3~+ in stage Ⅱ patients was lower than that in stage Ⅰ, and the differences were statistically significant(P<0.05). The CD8~+, CD4~+, CD3~+ and CD56~+ levels were compared between patients with or without lymph node metastasis in esophageal cancer group, and the differences were statistically significant(P>0.05).Conclusion The cellular immune function of patients with esophageal cancer declines, and the cellular immune function decreases with the increase of clinical stages.
引文
[1] CHEN W, ZHENG R, ZHANG S, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level[J]. Chin J Cancer Res, 2017, 29(1): 1-10.
[2] PENNATHUR A, GIBSON M K, JOBE B A, et al. Oesophageal carcinoma[J]. Lancet, 2013, 381(9864): 400-412.
[3] 刘倩, 孙爱民, 王玮. 固有免疫细胞抗肿瘤免疫治疗的研究进展[J]. 现代肿瘤医学, 2018, 26(8): 1292-1296.
[4] ZENG H, ZHENG R, GUO Y, et al. Cancer survival in China, 2003—2005: a population-based study[J]. Int J Cancer, 2015, 136(8): 1921-1930.
[5] 左婷婷, 郑荣寿, 曾红梅, 等. 中国食管癌发病状况与趋势分析[J]. 中华肿瘤杂志, 2016, 38(9): 703-708.
[6] 迟艳新. 肿瘤患者细胞免疫特征分析[J]. 中国卫生标准管理, 2017, 8(11): 110-112.
[7] 刘启胜, 杨志花, 卢学兵, 等. 食管癌患者NK细胞和T淋巴细胞免疫功能的检测及临床意义[J]. 现代消化及介入诊疗, 2016, 21(1): 1-3.
[8] 沈玉光, 高宗人, 许金良, 等. 流式细胞术对食管癌、贲门癌患者T细胞亚群的分析[J]. 肿瘤防治研究, 2006, 33(11): 818-820.
[9] SJOQUIST K M, BURMEISTER B H, SMITHERS B M, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis[J]. Lancet Oncol, 2011, 12(7): 681-692.
[2] PENNATHUR A, GIBSON M K, JOBE B A, et al. Oesophageal carcinoma[J]. Lancet, 2013, 381(9864): 400-412.
[3] 刘倩, 孙爱民, 王玮. 固有免疫细胞抗肿瘤免疫治疗的研究进展[J]. 现代肿瘤医学, 2018, 26(8): 1292-1296.
[4] ZENG H, ZHENG R, GUO Y, et al. Cancer survival in China, 2003—2005: a population-based study[J]. Int J Cancer, 2015, 136(8): 1921-1930.
[5] 左婷婷, 郑荣寿, 曾红梅, 等. 中国食管癌发病状况与趋势分析[J]. 中华肿瘤杂志, 2016, 38(9): 703-708.
[6] 迟艳新. 肿瘤患者细胞免疫特征分析[J]. 中国卫生标准管理, 2017, 8(11): 110-112.
[7] 刘启胜, 杨志花, 卢学兵, 等. 食管癌患者NK细胞和T淋巴细胞免疫功能的检测及临床意义[J]. 现代消化及介入诊疗, 2016, 21(1): 1-3.
[8] 沈玉光, 高宗人, 许金良, 等. 流式细胞术对食管癌、贲门癌患者T细胞亚群的分析[J]. 肿瘤防治研究, 2006, 33(11): 818-820.
[9] SJOQUIST K M, BURMEISTER B H, SMITHERS B M, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis[J]. Lancet Oncol, 2011, 12(7): 681-692.